The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Open accessAbstract
Psychosis is a common and distressing symptom in people with Alzheimer disease, and few safe and effective treatments are available. However, new approaches to symptom assessment and treatment are beginning to drive the field forward. New nosological perspectives have been provided by incorporating the emergence of psychotic symptoms in older adults - even in advance of dementia - into epidemiological and neurobiological frameworks as well as into diagnostic and research criteria such as the International Psychogeriatric Association criteria for psychosis in neurocognitive disorders, the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) research criteria for psychosis in neurodegenerative disease, and the ISTAART criteria for mild behavioural impairment. Here, we highlight the latest findings in genomics, neuroimaging and neurobiology that are informing approaches to drug discovery and repurposing. Current pharmacological and non-pharmacological treatment options are discussed, with a focus on safety and precision medicine. We also explore trial data for pimavanserin, a novel agent that shows promise for the treatment of psychosis in people with dementia, and discuss existing agents that might be useful but need further exploration such as escitalopram, lithium, cholinesterase inhibitors and vitamin D. Although the assessment and management of psychosis in people with dementia remain challenging, new opportunities are providing direction and hope to the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Methylphenidate, a dopamine transporter blocker that increases dopamine levels, seems to show mild improvement in apathy, the most prevalent disorder among the neuropsychiatric symptoms of AD [73].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [73]
Experimental — accuracy not yet measuredIn the citing paper
“the most prevalent disorder among the neuropsychiatric symptoms of AD [73]”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Self-citationCummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Self-citationSchneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Ismail, Z., Smith, E. E., Geda, Y., Sultzer, D., Brodaty, H., Smith, G., Agüera‐Ortiz, L., Sweet, R., Miller, D., Lyketsos, C. G., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.017 · Cited by 818
Self-citationPoint and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P., Lyketsos, C. G., Welsh‐Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 780
Self-citationMaust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3018 · Cited by 617
Self-citationKaufer, D., Cummings, J. L., Christine, D., Bray, T., Castellon, S., Masterman, D. L., MacMillan, A., Ketchel, P., & DeKosky, S. T. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02542.x · Cited by 607
Kales, H. C., Gitlin, L. N., Lyketsos, C. G., & Dementia, T. D. E. P. O. T. A. A. M. O. T. N. S. O. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12730 · Cited by 575
Self-citation
Research works printed but not linked: 2
- Nathan, S., Gill, S. & Ismail, Z. in Alzheimer’s Association International Conference (ALZ, 2020).
- Lussier, F. et al. Mild behavioral impairment is associated with beta-amyloid and tau across the alzheimer’s disease spectrum. J. Cereb. Blood Flow. Metab. 39, 158–159 (2019).
Cited by
Sorted by citations
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Self-citationWang, P., Yu, L., Gong, J., Xiong, J., Zi, S., Xie, H., Zhang, F., Mao, Z., Liu, Z., & Kim, J. S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202206894 · Cited by 163
Treatment for Alzheimer's disease
Fox, N. C., Belder, C. R. S., Ballard, C. G., Kales, H. C., Mummery, C. J., Caramelli, P., Ciccarelli, O., Frederiksen, K. S., Gómez‐Isla, T., Ismail, Z., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01329-7 · Cited by 137
Self-citationPless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
Rogowska, M., Thornton, M., Creese, B., Velayudhan, L., Aarsland, D., Ballard, C. G., Tsamakis, K., Stewart, R. J., & Mueller, C. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00992-5 · Cited by 110
Self-citationXu, L., Gao, H., Zhan, W., Deng, Y., Liu, X., Jiang, Q., Sun, X., Xu, J., & Liang, G. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10255 · Cited by 98
Hu, S., Patten, S. B., Charlton, A., Fischer, K., Fick, G. H., Smith, E. E., & Ismail, Z. (2022) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221093353 · Cited by 74
Self-citationChiral Nanoparticles Force Neural Stem Cell Differentiation to Alleviate Alzheimer's Disease
Shi, B., Zhao, J., Xu, Z., Chen, C., Xu, L., Xu, C., Sun, M., & Kuang, H. (2022) · Advanced Science · doi:10.1002/advs.202202475 · Cited by 69
Exosomes as CNS Drug Delivery Tools and Their Applications
Sun, K., Zheng, X., Jin, H., Yu, F. D., & Zhao, W. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102252 · Cited by 69
Liu, Y., Xiao, X., Yang, Y., Yao, R., Yang, Q., Zhu, Y., Yang, X., Zhang, S., Shen, L. H., & Jiao, B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14049 · Cited by 54
Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders
Cummings, J. L., Lanctôt, K. L., Grossberg, G. T., & Ballard, C. G. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0586 · Cited by 49
Self-citationConducting Polymer-Hydrogel Interpenetrating Networks for Improving the Electrode–Neural Interface
Yan, M., Wang, L., Wu, Y., Liao, X., Zhong, C., Wang, L., & Lu, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c07189 · Cited by 43
Neuropsychiatric symptoms in spinocerebellar ataxias and Friedreich ataxia
Karamazovová, S., Matušková, V., Ismail, Z., & Vyhnálek, M. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105205 · Cited by 45
Self-citationWang, X., Chen, S., Xia, X., Du, Y., Wei, Y., Yang, W., Zhang, Y., Song, Y., Lei, T., Huang, Q., et al. (2024) · Advanced Materials · doi:10.1002/adma.202411061 · Cited by 43
Ismail, Z., Ghahremani, M., Munir, M. A., Fischer, C. E., Smith, E. E., & Creese, B. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00043-x · Cited by 41
Self-citationIvraghi, M. S., Zamanian, M. Y., Gupta, R., Achmad, H., Alsaab, H. O., Hjazi, A. M., Romero‐Parra, R. M., Alwaily, E. R., Hussien, B. M., & Hakimizadeh, E. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14473 · Cited by 34
The neural basis of neuropsychiatric symptoms in Alzheimer’s disease
Zhang, N. K., Zhang, S. K., Zhang, L. I., Tao, H. W., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1487875 · Cited by 39
Teixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
Applications of Extracellular Vesicles in Nervous System Disorders: An Overview of Recent Advances
Khan, S. U., Khan, M. I., Khan, M. U., Khan, N. M., BUNGAU, S. G., & Hassan, S. S. U. (2022) · Bioengineering · doi:10.3390/bioengineering10010051 · Cited by 35
Creese, B., Arathimos, R., Aarsland, D., Ballard, C. G., Brooker, H. J., Hampshire, A., Corbett, A., & Ismail, Z. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12386 · Cited by 31
Self-citationCurrent therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Agüera-Ortíz, L., Babulal, G. M., Bruneau, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ismail, Z., Kumar, S., McGeown, W. J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215483 · Cited by 29
Self-citationVersatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
González-Bautista, E., Momméja, M., Mauléon, A. D., Ismail, Z., Vellas, B. J., Delrieu, J., & Martín, M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13902 · Cited by 26
Self-citationZhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26
Zong, B., Yu, F., Zhang, X., Zhao, W., Sun, P., Li, S., & Li, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.869507 · Cited by 31
Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy
Zhang, H., Peng, Y., Zhuo, L., Wang, Y., Guo, Z., Wang, S., Long, L., Li, X., & Wang, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114695 · Cited by 27
Thandivel, S., Poovarasan, R., Tamizharasan, G., Abisek, A., Khute, S., Kareti, S. R., & Subash, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27880 · Cited by 28
Navale, G. R., Ahmed, I., Lim, M. H., & Ghosh, K. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401991 · Cited by 24
Flexible multimaterial fibers in modern biomedical applications
Kim, J., & Jia, X. (2024) · National Science Review · doi:10.1093/nsr/nwae333 · Cited by 25
Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
Yu, X., Shao, K., Wan, K., Li, T., Li, Y., Zhu, X., & Han, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002566 · Cited by 23
Shan, X., Lu, Y., Luo, Z., Zhao, X., Mei, P., Yin, H., Guo, X., Zhou, H., Zhang, J., Huang, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01206 · Cited by 23
Nutrition: A non‐negligible factor in the pathogenesis and treatment of Alzheimer's disease
Wen, B., Han, X., Gong, J., Wang, P., Sun, W., Xu, C., Shan, A., Wang, X., Luan, H., Li, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14547 · Cited by 27
Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease
Ruthirakuhan, M. T., Guan, D. X., Mortby, M. E., Gatchel, J. R., & Babulal, G. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70079 · Cited by 23
Smeland, O. B., Kutrolli, G., Bahrami, S., Fominykh, V., Parker, N., Fuhrer, J., Hindley, G., Rødevand, L. N., Jaholkowski, P. P., Tesfaye, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02090-2 · Cited by 57
Angelopoulou, E., Koros, C., Hatzimanolis, A., Stefanis, L., Scarmeas, N., & Papageorgiou, S. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052645 · Cited by 23
Dementia Subtypes Defined Through Neuropsychiatric Symptom–Associated Brain Connectivity Patterns
Zhao, K., Xie, H., Fonzo, G. A., Carlisle, N. B., Osorio, R. S., & Zhang, Y. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.20479 · Cited by 23
Smeland, O. B., Kutrolli, G., Bahrami, S., Fominykh, V., Parker, N., Hindley, G., Rødevand, L. N., Jaholkowski, P. P., Tesfaye, M., Parekh, P., et al. (2023) · medRxiv · doi:10.1101/2023.07.21.23292993 · Cited by 23
Singh, S., Navale, G. R., Agrawal, S., Singh, H. K., Singla, L., Sarkar, D. M., Sarma, M., Choudhury, A. R., & Ghosh, K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124197 · Cited by 22
Niotis, K., Saperia, C., Saif, N., Carlton, C., & Isaacson, R. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00191-0 · Cited by 20
Kwon, K. J., Kim, H. Y., Han, S., & Shin, C. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111338 · Cited by 23
Wang, P., Yu, L., Gong, J., Xiong, J., Zi, S., Xie, H., Zhang, F., Mao, Z., Liu, Z., & Kim, J. S. (2022) · Angewandte Chemie · doi:10.1002/ange.202206894 · Cited by 20
Nirogi, R. V. S., Jayarajan, P., Benade, V. S., Shinde, A. K., Goyal, V., Jetta, S., Ravula, J., Abraham, R., Ramalingayya, G. V., Subramanian, R., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5813 · Cited by 17
Self-citationMatušková, V., Veverová, K., Jester, D. J., Maťoška, V., Ismail, Z., Sheardová, K., Horáková, H., Cerman, J., Laczó, J., Andel, R., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01386-y · Cited by 19
Self-citationEmerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease
Imbimbo, C., Ramusino, M. C., Leone, S., Mazzacane, F., Franco, V. D., Gatti, A., Perini, G., & Costa, A. C. (2024) · CNS Drugs · doi:10.1007/s40263-024-01133-9 · Cited by 20
Eickhoff, S., Franzen, L., Korda, A. I., Rogg, H. V., Trulley, V.-N., Borgwardt, S., & Avram, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.909961 · Cited by 17
Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers
Gomar, J. J., & Koppel, J. L. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.1389 · Cited by 18
The pleiotropic spectrum of proximal 16p11.2 CNVs
Auwerx, C., Kutalik, Z., & Reymond, A. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.08.015 · Cited by 19
Whey Protein Hydrolysate Renovates Age-Related and Scopolamine-Induced Cognitive Impairment
Ding, N., Meng, H., Wu, C., Yokoyama, W., Hong, H., Luo, Y., & Tan, Y. (2023) · Nutrients · doi:10.3390/nu15051228 · Cited by 18
Manca, R., Valera‐Bermejo, J. M., Venneri, A., & Initiative, A. D. N. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01417-5 · Cited by 16
Colavitta, M. F., Grasso, L., & Barrantes, F. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.5 · Cited by 15
Saizaki, T., Kubo, M., Sato, Y., Abe, H., Ohshiro, T., Mushiake, H., Sorin, F., & Guo, Y. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05046 · Cited by 14
Almeida, F., Jesus, T., Coelho, A., Quintas-Neves, M., Gauthreaux, K. M., Teylan, M., Mock, C., Kukull, W. A., Crary, J. F., & Oliveira, T. G. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.02.013 · Cited by 14
Beyond memory impairment: the complex phenotypic landscape of Alzheimer’s disease
Argyriou, S., Fullard, J. F., Krivinko, J. M., Lee, D., Wingo, T. S., Wingo, A. P., Sweet, R. A., & Roussos, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.04.016 · Cited by 13
Self-citationCognition and Cognitive Changes in a Low-Income Sub-Saharan African Aging Population
Kohler, I. V., Kämpfen, F., Bandawe, C., & Kohler, H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230271 · Cited by 13
Saini, R., Navale, G. R., Singh, S., Singh, H. K., Chauhan, R., Agrawal, S., Sarkar, D. M., Sarma, M., & Ghosh, K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125847 · Cited by 13
Seritan, A. L. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231164357 · Cited by 13
Image processing: an early detection tool for Alzheimer’s disease
Ballav, S., Biswas, B., Dey, S., Sahu, V. K., & Basu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00001-6 · Cited by 13
Psychotic Symptoms in Patients With Major Neurological Diseases
Kim, J. S., Hong, S. B., Park, K.-W., & Lee, A. T. C. (2024) · Journal of Clinical Neurology · doi:10.3988/jcn.2023.0501 · Cited by 15
A data‐driven examination of apathy and depressive symptoms in dementia with independent replication
Silva, M. V. D., Meléndez‐Torres, G. J., Ismail, Z., Testad, I., Ballard, C. G., Creese, B., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12398 · Cited by 11
Self-citationBera, T., Mondal, A., Kar, S., Mukherjee, A., Banerjee, S., & Guha, S. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01337a · Cited by 11
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders
Lozupone, M., Leccisotti, I., Mollica, A., Berardino, G., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., Dibello, V., Solfrizzi, V., et al. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01274 · Cited by 11
Xu, J., Liu, B., Shang, G., Feng, Z., Yang, H., Chen, Y., Yu, X., & Mao, Z. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70285 · Cited by 11
IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders
Gilchrist, L., Mutz, J., Hysi, P. G., Legido‐Quigley, C., Kõks, S., Lewis, C. M., & Proitsi, P. (2025) · BMC Medicine · doi:10.1186/s12916-025-04129-4 · Cited by 15
Valcic, M., Khoury, M. A., Kim, J., Fornazzari, L., Churchill, N. W., Ismail, Z., Luca, V. D., Tsuang, D. W., Schweizer, T. A., Muñoz, D. G., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12091266 · Cited by 11
Self-citationThe Janus face of antipsychotics in glial cells: Focus on glioprotection
Schmitz, I., da Silva, A., Bobermin, L. D., Gonçalves, C., Steiner, J. H., & Quincozes‐Santos, A. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231222027 · Cited by 11
Woldemariam, S. R., Tang, A., Oskotsky, T., Yaffe, K. S., & Sirota, M. (2023) · Communications Medicine · doi:10.1038/s43856-023-00280-2 · Cited by 10
Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer’s Disease
Tekade, A. R., Susar, R., Kulkarni, G., Surwade, S., & Gaikwad, A. (2024) · Current Alzheimer Research · doi:10.2174/0115672050288659240229080535 · Cited by 10
Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer’s Disease
Warren, H. T., Saeger, H. N., Tombari, R. J., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01696 · Cited by 10
DeMercy, H. M., & Brenner, C. A. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01134-9 · Cited by 10
Gibson, L. L., Mueller, C., Stewart, R. J., & Aarsland, D. (2024) · Psychological Medicine · doi:10.1017/s0033291724001922 · Cited by 10
Self-citationBlood-based biomarkers in mild behavioral impairment: an updated overview
Angelopoulou, E., Androni, X., Villa, C., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1534193 · Cited by 12
Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease
Wang, H. J., Chinna‐Meyyappan, A., Feldman, O. J., & Lanctôt, K. L. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2363215 · Cited by 9
Chemiexcitation-Triggered Photosensitizer Activation for Photooxidation of Aβ1–42 Aggregates
Liu, S., Yang, J., & Yan, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c06901 · Cited by 9
Neuroimaging Findings of Psychosis in Alzheimer's Disease: A Systematic Review
Nabizadeh, F., Sheykhlou, S., Mahmoodi, S., Khalili, E., Zafari, R., & Hosseini, H. (2024) · Brain and Behavior · doi:10.1002/brb3.70205 · Cited by 9
Kanemoto, H., Kashibayashi, T., Takahashi, R., Suehiro, T., Satake, Y., Taomoto, D., Chadani, Y., Tagai, K., Shinagawa, S., Ishii, K., et al. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100059 · Cited by 9
Stroud, J., Cummings, J. L., Chumki, S. R., Such, P., Wang, D., Palma, A. M., Zhang, Z., Brubaker, M., & Grossberg, G. T. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2552278 · Cited by 9
Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease
Gibson, L. L., Pollak, T. A., Heslegrave, A., Hye, A., Batzu, L., Rota, S., Trivedi, D., Nicholson, T. R., Ffytche, D. H., Zetterberg, H., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223182 · Cited by 8
Self-citationDistinct and shared neuropsychiatric phenotypes in FTLD-tauopathies
Keszycki, R. M., Kawles, A., Minogue, G., Zouridakis, A., Macomber, A. J., Gill, N. P., Vu, M. H., Zhang, H., Coventry, C., Rogalski, E. J., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1164581 · Cited by 7
Anticholinergic burden and incident dementia: a Swedish nationwide case-control study
Zhu, N., Eriksdotter, M., Liabeuf, S., Tan, E. C. K., Johnell, K., Ptacek, S. G., & Xu, H. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01883-8 · Cited by 8
Alzheimer’s disease and clinical trials
Paul, D., Agrawal, R., & Singh, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0264 · Cited by 7
Robbins-Welty, G. A., Riordan, P. A., Shalev, D., Chammas, D., Noufi, P. E., Brenner, K. O., Briscoe, J. G., Rosa, W. E., & Webb, J. A. (2024) · Journal of Palliative Medicine · doi:10.1089/jpm.2024.0135 · Cited by 9
Xiong, S., Cui, M., Liu, H., Wu, L., Xiong, X., Zhang, S., Yang, J., & Wang, P. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c04718 · Cited by 7
Sharma, B., Das, S., Mazumder, A., Rautela, D. S., Tyagi, P. K., & Khurana, N. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00848-2 · Cited by 8
Scarfo, S., Marsella, A. M. A., Grigoriadou, L., Moshfeghi, Y., & McGeown, W. J. (2024) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2024.109006 · Cited by 6
A brain DNA co‐methylation network analysis of psychosis in Alzheimer's disease
Kouhsar, M. P., Weymouth, L. S., Smith, A. R., Imm, J. L., Bredemeyer, C., Wedatilake, Y., Torkamani, A., Bergh, S., Selbæk, G., Mill, J. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14501 · Cited by 8
Self-citationNeuropsychiatric symptoms in AD: the search for mechanisms
Creese, B., & Lunnon, K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00721-x · Cited by 6
Self-citationAndrade, C. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23f15009 · Cited by 6
Hojjati, S. H., Chen, K., Chiang, G. C.-Y., Kuceyeski, A. F., Wang, X. H., Razlighi, Q. R., Pahlajani, S. S., Glodzik, L., Tanzi, E. B., Reinhardt, M., et al. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115386 · Cited by 5
Wang, L., Venkatesh, S., Morris, M. M., Li, M., Srivastava, R., Visweswaran, S., López, O. L., Xia, Z., & Cai, T. (2026) · Communications Medicine · doi:10.1038/s43856-026-01511-y · Cited by 5
Chen, D., Zhu, Z., Shi, Y., Li, H., & Li, H. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105259 · Cited by 5
Prevalence of psychotic symptoms in mild cognitive impairment: A systematic review and meta-analysis
Berger, A., Castilhos, R. M., Ismail, Z., & de Pádua, A. C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102431 · Cited by 5
Self-citationPsychosis associated with dementia: evaluation and management
Tampi, R. R., Joshi, P., & Jeste, D. V. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.04.022 · Cited by 6
Neuropsychiatric Manifestations in Alzheimer’s Disease Patients: Genetics and Treatment Options
Singh, A. K., Malviya, R., Prakash, A., & Verma, S. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230301111216 · Cited by 5
Presenilin Gene Mutation-associated Psychosis
Colijn, M. A., & Ismail, Z. (2024) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000599 · Cited by 5
Self-citationPsychosis detection in dementia: a systematic review of diagnostic test accuracy studies
Atchison, K., Wu, P., Watt, J. A., Seitz, D. P., Ismail, Z., & Goodarzi, Z. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1377191 · Cited by 6
Self-citationde Miranda, A. S., Macêdo, D. S., Sanders, L. L. O., Monte, A. S., Soares, M. V. R., & Teixeira, A. L. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111429 · Cited by 5
Exploring Psychosis in Neurodegenerative Dementia: Connecting Symptoms to Neurobiology
Morrow, C. B., & Pontone, G. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240328 · Cited by 4
Wu, C., Chen, S., Huang, W., Zhao, K., Fang, C., Liu, F., Zhang, Y., & Li, H. (2025) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2025.126200 · Cited by 4
Metadata
- Authors
- Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C.
- Affiliations
- University of Calgary (CA)
- University of Exeter (GB)
- King's College London (GB)
- University of California Davis Medical Center (US)
- Johns Hopkins University (US)
- University of Pittsburgh (US)
- Corresponding author
- Ballard, Clive
- ORCID
- Venue
- Nature Reviews Neurology
- Published
- 2022-01-04
- Volume
- 18
- Issue
- 3
- Pages
- 131-144
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC9074132
- OpenAlex
- W4205106947
- Cited by
- 189
- References
- 179
- Citations by year
- 2026: 24 · 2025: 47 · 2024: 61 · 2023: 32 · 2022: 25
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Reviews Neurology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Brunel University Research Archive (BURA) (Brunel University London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Biogen
- Fondation Brain Canada
- Sunovion
- National Football League Players Association
- Eisai
- Astellas Pharma
- Servier
- H. Lundbeck A/S
- Genentech
- National Institute on Aging (P30AG066468, P30AG066507)
- National Institute of Mental Health (R01MH116046)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- dementia, drug repurposing, pimavanserin, escitalopram, lithium, cholinesterase inhibitors, vitamin D, non-pharmacological treatment, precision medicine, neuroimaging, neurobiology of psychosis
- MeSH terms
- Aged, Alzheimer Disease, Humans, Psychotic Disorders, Neurodegenerative Diseases, Neurocognitive Disorders, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
